scholarly journals Landscapes and bacterial signatures of mucosa-associated intestinal microbiota in Chilean and Spanish patients with inflammatory bowel disease

2021 ◽  
Author(s):  
Nayareth Chamorro ◽  
David A. Montero ◽  
Pablo Gallardo ◽  
Mauricio Farfan ◽  
Mauricio Contreras ◽  
...  
Keyword(s):  
Intestinal Microbiota ◽  
Diagnostic Methods ◽  
Aerobic Bacteria ◽  
Healthy Individuals ◽  
Beneficial Bacteria ◽  
Facultative Anaerobe ◽  
Non Invasive ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Colonic Biopsies

Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), cause chronic inflammation of the gut, affecting millions of people worldwide. IBD have been frequently associated with an alteration of the gut microbiota, termed dysbiosis, which is generally characterized by an increase in abundance of Proteobacteria such as Escherichia coli, and a decrease in abundance of Firmicutes such as Faecalibacterium prausnitzii (an indicator of a healthy colonic microbiota). The mechanisms behind the development of the IBD and the dysbiosis are incompletely understood. Using samples from colonic biopsies, we studied the mucosa-associated intestinal microbiota in Chilean and Spanish patients with IBD. In agreement with previous studies, microbiome comparison between IBD patients and non-IBD controls indicated that dysbiosis in these patients is characterized by an increase of pro-inflammatory bacteria (mostly Proteobacteria) and a decrease of commensal beneficial bacteria (mostly Firmicutes). Notably, bacteria typically residing on the mucosa of healthy individuals were mostly obligate anaerobes, whereas in the inflamed mucosa an increase of facultative anaerobe and aerobic bacteria was observed. We also identify potential co-occurring and mutually exclusive interactions between bacteria associated with the healthy and inflamed mucosa, which appear to be determined by the oxygen availability and the type of respiration. Finally, we identify a panel of bacterial biomarkers that allow the discrimination between eubiosis from dysbiosis with a high diagnostic performance (96% accurately), which could be used for the development of non-invasive diagnostic methods. Thus, this study is a step forward toward understanding the landscapes and alterations of mucosa-associated intestinal microbiota in patients with IBD.

scholarly journals Landscapes and bacterial signatures of mucosa-associated intestinal microbiota in Chilean and Spanish patients with inflammatory bowel disease

2021 ◽  
Vol 8 (9) ◽  
pp. 223-238
Author(s):  
Nayaret Chamorro ◽  
David A. Montero ◽  
Pablo Gallardo ◽  
Mauricio Farfán ◽  
Mauricio Contreras ◽  
...  
Keyword(s):  
Intestinal Microbiota ◽  
Diagnostic Methods ◽  
Aerobic Bacteria ◽  
Healthy Individuals ◽  
Beneficial Bacteria ◽  
Facultative Anaerobe ◽  
Non Invasive ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Colonic Biopsies

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), cause chronic inflammation of the gut, affecting millions of people worldwide. IBDs have been frequently associated with an alteration of the gut microbiota, termed dysbiosis, which is generally characterized by an increase in abundance of Proteobacteria such as Escherichia coli, and a decrease in abundance of Firmicutes such as Faecalibacterium prausnitzii (an indicator of a healthy colonic microbiota). The mechanisms behind the development of IBDs and dysbiosis are incompletely understood. Using samples from colonic biopsies, we studied the mucosa-associated intestinal microbiota in Chilean and Spanish patients with IBD. In agreement with previous studies, microbiome comparison between IBD patients and non-IBD controls indicated that dysbiosis in these patients is characterized by an increase of pro-inflammatory bacteria (mostly Proteobacteria) and a decrease of commensal beneficial bacteria (mostly Firmicutes). Notably, bacteria typically residing on the mucosa of healthy individuals were mostly obligate anaerobes, whereas in the inflamed mucosa an increase of facultative anaerobe and aerobic bacteria was observed. We also identify potential co-occurring and mutually exclusive interactions between bacteria associated with the healthy and inflamed mucosa, which appear to be determined by the oxygen availability and the type of respiration. Finally, we identified a panel of bacterial biomarkers that allow the discrimination between eubiosis from dysbiosis with a high diagnostic performance (96% accurately), which could be used for the development of non-invasive diagnostic methods. Thus, this study is a step forward towards understanding the landscapes and alterations of mucosa-associated intestinal microbiota in patients with IBDs.

scholarly journals Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD

Biomolecules ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1903
Author(s):  
Adrian Martyniak ◽  
Aleksandra Medyńska-Przęczek ◽  
Andrzej Wędrychowicz ◽  
Szymon Skoczeń ◽  
Przemysław J. Tomasik
Keyword(s):  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Immunological Response ◽  
Bacterial Metabolism ◽  
Dietary Fibers ◽  
Beneficial Bacteria ◽  
New Methods ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The increasing incidence of inflammatory bowel diseases (IBD) and the increasing severity of the course of these diseases create the need for developing new methods of therapy. The gut microbiome is extensively studied as a factor influencing the development and course of IBD. The composition of intestinal microbiota can be relatively easily modified by diet (i.e., prebiotics, mainly dietary fibers) and bacterial supplementation using beneficial bacteria strains called probiotics. Additionally, the effects of the improved microbiome could be enhanced or gained by using paraprobiotics (non-viable, inactivated bacteria or their components) and/or postbiotics (products of bacterial metabolism or equal synthetic products that beneficially modulate immunological response and inflammation). This study summarizes the recent works on prebiotics, probiotics, synbiotics (products merging pre- and probiotics), paraprobiotics and postbiotics in IBD.

scholarly journals The usefulness of fecal calprotectin testing in pediatric gastroenterology clinical practice

2020 ◽  
Author(s):  
Eliza Lężyk-Ciemniak ◽  
Magdalena Tworkiewicz ◽  
Dominika Wilczyńska ◽  
Anna Szaflarska-Popławska ◽  
Aneta Krogulska
Keyword(s):  
Gastrointestinal Tract ◽  
Intestinal Inflammation ◽  
Fecal Calprotectin ◽  
Diagnostic Methods ◽  
Delay In Diagnosis ◽  
Number Of Children ◽  
Non Invasive ◽  
Course Of Action ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract Gastrointestinal tract symptoms such as abdominal pain, constipation, diarrhea, and fever are frequent causes of visits to the pediatrician. The increasing prevalence of chronic gastrointestinal tract diseases, and the falling median age of their onset, indicate the need to identify new diagnostic methods that can differentiate inflammatory bowel diseases from other gastrointestinal tract conditions. A promising non-invasive and useful marker of intestinal inflammation is fecal calprotectin. The manuscript summarizes currently available information on the use of fecal calprotectin in the diagnosis and monitoring of inflammatory bowel disease in children. It also attempts to determine the effect of concentration on its course of action. Incorporating fecal calprotectin (FC) testing within the framework of primary medical care can decrease the number of children unnecessarily referred for endoscopic or radiologic examination. FC screening benefits patients by reducing any delay in diagnosis and avoiding unnecessary exposure to endoscopy, and benefits physicians by reducing pressure on endoscopy testing and assisting the decision. The present paper emphasizes the role of fecal calprotectin as a non-invasive marker for monitoring disease activity and efficacy of therapy, and predicting postoperative relapses, primarily in patients with IBD.

INFLAMMATORY BOWEL DISEASES AND FOOD ALLERGY: PATHOGENETIC AND CLINICAL PARALLELS

2021 ◽  
Vol 100 (1) ◽  
pp. 112-119
Author(s):  
S.G. Makarova ◽  
◽  
I.G. Gordeeva ◽  
A.N. Surkov ◽  
◽  
...  
Keyword(s):  
Food Allergy ◽  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Transforming Growth Factor ◽  
Clinical Manifestations ◽  
Allergic Diseases ◽  
Diagnostic Methods ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Endoscopic Picture

Inflammatory bowel diseases (IBD), like allergic diseases, are referred to «diseases of civilization», and their prevalence is growing throughout the world, including in the pediatric population. Both diseases refer to immunopathological conditions and have not only some common pathogenesis, but also similar clinical picture. It is also known about common factors that contribute to the predisposition to both groups of diseases – both genetic and environmental – vitamin D deficiency, changes in the intestinal microbiota composition etc. However, the mechanisms of observed relationship between IBD and food allergy (FA) are not fully understood. In this review, devoted to the current state of the problem, the pathogenetic and clinical parallels between FA and IBD are considered in detail. FA gastrointestinal symptoms may not differ from IBD onset, and the endoscopic picture may mimic the symptoms seen in patients with IBD. Indeed, the verification of gastrointestinal FA is still difficult due to the lack of reliable laboratory diagnostic methods. Besides misdiagnosis, comorbidity between FA and IBD is described. The complex pathogenetic mechanism of both IBD and allergic reactions is based on eosinophils, helper Th2 and Th17 cells, and transforming growth factor β. The common pathogenetic mechanisms lead to similar clinical manifestations, when not only the digestive system, but also the respiratory system and skin can be affected, although this is much less common in IBD. An important role is played by intestinal barrier state and intestinal microbiota – it was revealed that in children with certain genotypes, intestinal dysbiosis can cause immune abnormalities, leading to both allergic diseases and IBD.

scholarly journals The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review)

2020 ◽  
Vol 48 (6) ◽  
pp. 364-374
Author(s):  
D. А. Kuznetsova ◽  
S. V. Lapin ◽  
O. B. Shchukina
Keyword(s):  
Differential Diagnosis ◽  
Prognostic Significance ◽  
Immunological Tolerance ◽  
Genetically Engineered ◽  
Diagnostic Methods ◽  
Serological Markers ◽  
Diagnosis And Prognosis ◽  
Bowel Diseases ◽  
Risk Of Progression ◽  
Inflammatory Bowel

The diagnosis of inflammatory bowel disease (IBD) is based on a combination of clinical, endoscopic, histological, radiological and laboratory methods. However, conventional diagnostic methods are not always sufficiently informative in IBD, especially in the case of unclassified colitis, which necessitates the extension of standard diagnostic approaches. Currently, there is an actively search for non-invasive serological markers for early and differential diagnosis of IBD and for the assessment of activity and prognosis of Crohn's disease (CD) and ulcerative colitis (UC). Among the most interesting serological markers are anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), goblet cells antibodies (GAB) and pancreatic autoantibodies (PAB). The aim of this review is to assess the diagnostic and prognostic significance of ASCA, ANCA, GAB, PAB in CD and UC. The paper presents the summary of the data on the role of ASCA, ANCA, GAB and PAB in abnormalities of the immunological tolerance mechanisms to intestinal microflora and intestinal permeability in IBD. We discuss the results of the studies on the associations of ASCA with a complicated CD phenotype, its response to genetically engineered biological therapies, and the need for surgical intervention. The article describes the data on the association of ANCA to the risk of progression of left-sided UC to widespread (total) colon lesions resistant to hormonal therapy, and that of antibodies to DNA-lactoferrin complexes and proteinase 3 to primary sclerosing cholangitis. It has been noted that PAB may be a prognostic marker for ileocolitis, perianal lesions, extraintestinal manifestations and complicated CD, and GAB a  predictor of total UC with chronic persistent course. It should be emphasized that combined determination of ASCA, ANCA, GAB and PAB is highly informative, compared to the isolated detection of autoantibodies, for the differential diagnosis and prognosis of CD and UC.

Increased serum nesfatin-1 levels in patients with inflammatory bowel diseases

2021 ◽  
pp. postgradmedj-2020-139227
Author(s):  
Şengül Beyaz ◽  
Erdem Akbal
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Inflammatory Diseases ◽  
Inflammatory Marker ◽  
White Cell Count ◽  
Characteristic Curve ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Altered Expression ◽  
Bowel Diseases ◽  
Inflammatory Bowel

BackgroundAdipokines are adipose tissue–derived secreted molecules that can exert anti-inflammatory or proinflammatory activities. Altered expression of adipokines has been described in various inflammatory diseases, including inflammatory bowel diseases (IBDs) such as Crohn’s disease (CD) and ulcerative colitis (UC). Little is known about nesfatin-1, a recently identified adipokine, in IBD. The aim of this study was to investigate serum nesfatin-1 levels in patients with IBD.MethodsThis study included a total of 52 adult individuals (17 patients with CD, 18 patients with UC and 17 healthy volunteers) with similar age and body mass index. Serum nesfatin-1 levels were measured by ELISA in healthy individuals and patients with IBD in their active and remission periods. Blood inflammation markers including C reactive protein (CRP), erythrocyte sedimentation (ESR) and white cell count (WCC) were also measured in patients.ResultsWe found significantly elevated levels of serum nesfatin-1 in the active disease period in both patients with CD (p=0.00003) and patients with UC (p=0.00001), compared with healthy individuals. Serum nesfatin-1 levels moderately decreased in the remission period; however, they were still significantly higher than that of healthy individuals. Receiver operating characteristic curve analyses indicated serum nesfatin-1 with an excellent diagnostic value for IBD. Finally, patients had significantly high CRP, ESR and WCC in the active IBD; however, we found the nesfatin-1 strongly correlated only with ESR in the active CD.ConclusionThis is the first study investigating the circulating levels of nesfatin-1 in patients with IBD. Serum nesfatin-1 may serve as an additional inflammatory marker for diagnosis of IBD in affected individuals.

scholarly journals Interplay of intestinal microbiota and mucosal immunity in inflammatory bowel disease: a relationship of frenemies

2020 ◽  
Vol 13 ◽  
pp. 175628482093518
Author(s):  
Huimin Chen ◽  
Hongfen Li ◽  
Zhanju Liu
Keyword(s):  
Immune Response ◽  
Intestinal Microbiota ◽  
Mucosal Immunity ◽  
Therapeutic Response ◽  
Mucosal Immune Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Novel Approaches ◽  
Relationship Of ◽  
Lines Of Evidence

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, are chronic inflammatory disorders of the gastrointestinal tract. With in-depth studies on the mechanisms of the initiation and development of IBD, increasing lines of evidence have focused on the intestinal microbiota in the pathogenesis of IBD. The imbalance between the host and intestinal microbiota induces dysregulated immune response in intestinal mucosa and plays a pivotal role in the initiation of disease and ongoing bowel destruction. This review focuses on recent advances in intestinal microbiota regulation of mucosal immune response as well as novel approaches based on intestinal microbiota alterations in the diagnosis and evaluation of therapeutic response in IBD.

Protective effects of a novel probiotic strain, Lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence

2019 ◽  
Vol 10 (2) ◽  
pp. 1132-1145 ◽  
Author(s):  
Meiling Liu ◽  
Xiuxia Zhang ◽  
Yunpeng Hao ◽  
Jinhua Ding ◽  
Jing Shen ◽  
...  
Keyword(s):  
Immune Responses ◽  
Lactococcus Lactis ◽  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Probiotic Strain ◽  
Protective Effects ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Multiple articles have confirmed that an imbalance of the intestinal microbiota is closely related to aberrant immune responses of the intestines and to the pathogenesis of inflammatory bowel diseases (IBDs).

Sign in / Sign up

Export Citation Format

Share Document